134 related articles for article (PubMed ID: 15724801)
1. High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill.
Guzelmeric K; Seker N; Unal O; Turan C
Gynecol Endocrinol; 2004 Oct; 19(4):190-5. PubMed ID: 15724801
[TBL] [Abstract][Full Text] [Related]
2. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills.
Escobar-Morreale HF; Avila S; Sancho J
J Clin Endocrinol Metab; 2000 Jul; 85(7):2488-92. PubMed ID: 10902798
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of prostate-specific antigen and androgens after nasal administration of a gonadotropin releasing hormone-agonist in hirsute women.
Kocak M; Tarcan A; Beydilli G; Koç S; Haberal A
Gynecol Endocrinol; 2004 Apr; 18(4):179-85. PubMed ID: 15293888
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women.
Negri C; Tosi F; Dorizzi R; Fortunato A; Spiazzi GG; Muggeo M; Castello R; Moghetti P
J Clin Endocrinol Metab; 2000 Jan; 85(1):81-4. PubMed ID: 10634368
[TBL] [Abstract][Full Text] [Related]
5. Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+desogestrel/ethinyl estradiol combination.
Bahceci M; Bilge M; Tuzcu A; Tuzcu S; Bahceci S
J Endocrinol Invest; 2004 Apr; 27(4):353-6. PubMed ID: 15233555
[TBL] [Abstract][Full Text] [Related]
6. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
Frölich M; Lachinsky N; Moolenaar AJ
Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
Sobbrio GA; Granata A; D'Arrigo F; Arena D; Panacea A; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):139-41. PubMed ID: 2149912
[TBL] [Abstract][Full Text] [Related]
8. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
Wild RA; Demers LM; Applebaum-Bowden D; Lenker R
Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706
[TBL] [Abstract][Full Text] [Related]
9. Changes in androgens during treatment with four low-dose contraceptives.
Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
[TBL] [Abstract][Full Text] [Related]
10. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
[TBL] [Abstract][Full Text] [Related]
12. The effect of an oral contraceptive containing ethinylestradiol and desogestrel on hair growth and hormonal parameters of hirsute women.
Ruutiainen K
Int J Gynaecol Obstet; 1986 Oct; 24(5):361-8. PubMed ID: 2880770
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
[TBL] [Abstract][Full Text] [Related]
14. Predictors of clinical response in hirsute women treated with spironolactone.
Crosby PD; Rittmaster RS
Fertil Steril; 1991 Jun; 55(6):1076-81. PubMed ID: 1828043
[TBL] [Abstract][Full Text] [Related]
15. Androsterone sulfate: physiology and clinical significance in hirsute women.
Zwicker H; Rittmaster RS
J Clin Endocrinol Metab; 1993 Jan; 76(1):112-6. PubMed ID: 8380602
[TBL] [Abstract][Full Text] [Related]
16. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D; Smith S; Zacur H
Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
18. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.
Acién P; Mauri M; Gutierrez M
Hum Reprod; 1997 Mar; 12(3):423-9. PubMed ID: 9130733
[TBL] [Abstract][Full Text] [Related]
19. Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
Maier PS; Spritzer PM
Gynecol Obstet Invest; 2012; 74(2):136-42. PubMed ID: 22889864
[TBL] [Abstract][Full Text] [Related]
20. The effect of different contraceptive treatments on the serum concentration of dehydroepiandrosterone sulfate.
Klove KL; Roy S; Lobo RA
Contraception; 1984 Apr; 29(4):319-24. PubMed ID: 6235099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
